Oncotarget

Research Papers:

Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis

Ling Cao, Yong-Jing Yang, Zhi-Wen Li, Hong-Fen Wu, Zhu-Chun Yang, Shi-Xin Liu and Ping Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:2647-2658. https://doi.org/10.18632/oncotarget.13735

Metrics: PDF 1930 views  |   HTML 2043 views  |   ?  


Abstract

Ling Cao1, Yong-Jing Yang1, Zhi-Wen Li2, Hong-Fen Wu1, Zhu-Chun Yang1, Shi-Xin Liu1, Ping Wang3

1Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People’s Republic of China

2Department of Anesthesiology, The First Hospital Affiliated to Jilin University, Changchun 130012, People’s Republic of China

3Department of Radiotherapy, Cancer Institute and Hospital of Tianjin Medical University, Tianjin 300060, People’s Republic of China

Correspondence to:

Shi-Xin Liu, email: [email protected]

Ping Wang, email: [email protected]

Keywords: prostatic neoplasms, hypofractionation, radiotherapy, meta-analysis

Received: August 08, 2016     Accepted: November 24, 2016     Published: December 01, 2016

ABSTRACT

To compare the efficacy and safety of moderate hypofractionated radiotherapy (H-RT) with those of conventional radiotherapy (C-RT) in patients with localized prostate cancer, we conducted extensive literature searches of The Web of Science, Embase, Pubmed and Cochrane Library databases. We identified nine studies with 5969 patients for a meta-analysis. We calculated pooled risk ratios (RRs) and the 95% confidence intervals (CIs) for multiple parameters and performed statistical analysis using RevMan 5.3 software. Our analysis showed that the H-RT group obtained greater improvements in the 5-year biochemical or clinical failure-free survival (RR = 1.04, 95% CI:1.01–1.08; P = 0.01) and 5-year disease-free survival(RR = 1.04, 95% CI: 1.01–1.07, P = 0.02) than the C-RT group. However, the 5-year overall survival rates were comparable in the two groups (RR = 1.02, 95% CI: 0.99–1.04; P = 0.18). Comparison of multiple secondary parameters, including grade 2-4 acute/late gastrointestinal toxicity, grade 2–4 acute/late genitourinary toxicity, biochemical failure, local failure, distant failure and prostate cancer-specific mortality between the H-RT and the C-RT groups showed no statistical differences. This meta-analysis thus indicates that in patients with localized prostate cancer, moderate H-RT exerts a great beneficial effect on the primary parameters than C-RT without enhancing adverse events.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13735